FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077777928> ?p ?o ?g. }

• W2077777928 endingPage "5156" @default.
• W2077777928 startingPage "5151" @default.
• W2077777928 abstract "Abstract This phase 2 study evaluated the efficacy and safety of the oral farnesyltransferase inhibitor tipifarnib in adults with refractory or relapsed acute myeloid leukemia (AML). Patients (n = 252) received tipifarnib 600 mg twice a day for 21 days in 28-day cycles. Median age was 62 years; 99 (39%) patients were 65 years or older. Eleven (4%) of 252 patients achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp; 9 CR and 2 CRp). Nineteen patients (8%), including those who achieved CR/CRp, achieved a reduction in bone marrow blasts to less than 5% blasts. Bone marrow blasts were reduced more than 50% in an additional 8 patients (total = 27; 11%). Median survival was 369 days for patients who achieved CR/CRp. Myelosuppression was the most common adverse event. The most common nonhematologic toxicities were fever, nausea, and hypokalemia. Single-agent treatment with tipifarnib induced durable CR/CRp, which was associated with prolonged survival, in some patients with refractory or relapsed AML. The response rate observed in this heavily pretreated group of patients suggests the requirement to enhance the response rate either by combining tipifarnib with other active agents or determining factors that are predictive of response." @default.
• W2077777928 created "2016-06-24" @default.
• W2077777928 creator A5002061358 @default.
• W2077777928 creator A5004066423 @default.
• W2077777928 creator A5014838075 @default.
• W2077777928 creator A5018361694 @default.
• W2077777928 creator A5041443589 @default.
• W2077777928 creator A5046775582 @default.
• W2077777928 creator A5058334809 @default.
• W2077777928 creator A5061992932 @default.
• W2077777928 creator A5071023119 @default.
• W2077777928 creator A5072721892 @default.
• W2077777928 creator A5087474154 @default.
• W2077777928 date "2007-06-15" @default.
• W2077777928 modified "2023-10-03" @default.
• W2077777928 title "A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia" @default.
• W2077777928 cites W11751756 @default.
• W2077777928 cites W194463696 @default.
• W2077777928 cites W1955547739 @default.
• W2077777928 cites W1996254906 @default.
• W2077777928 cites W1996987411 @default.
• W2077777928 cites W2002267072 @default.
• W2077777928 cites W2025754007 @default.
• W2077777928 cites W2072341673 @default.
• W2077777928 cites W2079472461 @default.
• W2077777928 cites W2102901804 @default.
• W2077777928 cites W2122756958 @default.
• W2077777928 cites W2125244026 @default.
• W2077777928 cites W2125877707 @default.
• W2077777928 cites W2133013399 @default.
• W2077777928 cites W2140291353 @default.
• W2077777928 cites W2141817518 @default.
• W2077777928 cites W2143568970 @default.
• W2077777928 cites W2151222524 @default.
• W2077777928 cites W2153345005 @default.
• W2077777928 cites W2159507916 @default.
• W2077777928 cites W2204433245 @default.
• W2077777928 cites W2979946515 @default.
• W2077777928 cites W4376595466 @default.
• W2077777928 doi "https://doi.org/10.1182/blood-2006-09-046144" @default.
• W2077777928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17351110" @default.
• W2077777928 hasPublicationYear "2007" @default.
• W2077777928 type Work @default.
• W2077777928 sameAs 2077777928 @default.
• W2077777928 citedByCount "73" @default.
• W2077777928 countsByYear W20777779282012 @default.
• W2077777928 countsByYear W20777779282013 @default.
• W2077777928 countsByYear W20777779282014 @default.
• W2077777928 countsByYear W20777779282015 @default.
• W2077777928 countsByYear W20777779282016 @default.
• W2077777928 countsByYear W20777779282017 @default.
• W2077777928 countsByYear W20777779282019 @default.
• W2077777928 countsByYear W20777779282021 @default.
• W2077777928 countsByYear W20777779282022 @default.
• W2077777928 countsByYear W20777779282023 @default.
• W2077777928 crossrefType "journal-article" @default.
• W2077777928 hasAuthorship W2077777928A5002061358 @default.
• W2077777928 hasAuthorship W2077777928A5004066423 @default.
• W2077777928 hasAuthorship W2077777928A5014838075 @default.
• W2077777928 hasAuthorship W2077777928A5018361694 @default.
• W2077777928 hasAuthorship W2077777928A5041443589 @default.
• W2077777928 hasAuthorship W2077777928A5046775582 @default.
• W2077777928 hasAuthorship W2077777928A5058334809 @default.
• W2077777928 hasAuthorship W2077777928A5061992932 @default.
• W2077777928 hasAuthorship W2077777928A5071023119 @default.
• W2077777928 hasAuthorship W2077777928A5072721892 @default.
• W2077777928 hasAuthorship W2077777928A5087474154 @default.
• W2077777928 hasBestOaLocation W20777779281 @default.
• W2077777928 hasConcept C121332964 @default.
• W2077777928 hasConcept C126322002 @default.
• W2077777928 hasConcept C141071460 @default.
• W2077777928 hasConcept C142424586 @default.
• W2077777928 hasConcept C181199279 @default.
• W2077777928 hasConcept C185592680 @default.
• W2077777928 hasConcept C197934379 @default.
• W2077777928 hasConcept C2776694085 @default.
• W2077777928 hasConcept C2777827897 @default.
• W2077777928 hasConcept C2778396349 @default.
• W2077777928 hasConcept C2778729363 @default.
• W2077777928 hasConcept C2780007613 @default.
• W2077777928 hasConcept C2780580376 @default.
• W2077777928 hasConcept C31760486 @default.
• W2077777928 hasConcept C55493867 @default.
• W2077777928 hasConcept C57790582 @default.
• W2077777928 hasConcept C71924100 @default.
• W2077777928 hasConcept C87355193 @default.
• W2077777928 hasConcept C90924648 @default.
• W2077777928 hasConceptScore W2077777928C121332964 @default.
• W2077777928 hasConceptScore W2077777928C126322002 @default.
• W2077777928 hasConceptScore W2077777928C141071460 @default.
• W2077777928 hasConceptScore W2077777928C142424586 @default.
• W2077777928 hasConceptScore W2077777928C181199279 @default.
• W2077777928 hasConceptScore W2077777928C185592680 @default.
• W2077777928 hasConceptScore W2077777928C197934379 @default.
• W2077777928 hasConceptScore W2077777928C2776694085 @default.
• W2077777928 hasConceptScore W2077777928C2777827897 @default.
• W2077777928 hasConceptScore W2077777928C2778396349 @default.
• W2077777928 hasConceptScore W2077777928C2778729363 @default.

• next